Glycomed Inc. said Monday that it has filed its previouslyannounced secondary offering of 2 million shares of commonstock (NASDAQ:GLYC). Underwriters Montgomery Securities andHambrecht & Quist have an option to buy 300,000 additionalshares to cover overallotments. Alameda, Calif.-basedGlycomed is developing drugs based on complex carbohydratesto treat cardiovascular and inflammatory diseases, and fortissue repair. The stock closed at $10.75, up 50 cents onMonday.

(c) 1997 American Health Consultants. All rights reserved.